The divestiture allows CareDx to focus on its core testing services business while receiving $170 million in cash. The strong 48% year-over-year growth in testing services revenue suggests the core business is performing well. The distribution agreement with Eurobio provides ongoing revenue from the divested products.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 16 $22.42entry
- T+1 · 7mo ago −4.46%α −5.67% · $21.42
- T+5 · 7mo ago −10.53%α −11.51% · $20.06
- T+20 · 6mo ago −8.07%α −13.89% · $20.61
- T+60 · 4mo ago +28.28%α +21.23% · $28.76
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CareDx is divesting its lab products business to Eurobio Scientific for $170 million in cash to focus on core testing services, while reporting preliminary Q1 2026 revenue of $118 million with 48% year-over-year growth in testing services revenue. The transaction includes a 6-month transition services agreement and a distribution agreement for North America.
Key Financial Metrics
Key Facts
- Divesting lab products business to Eurobio Scientific for $170 million in cash
- Preliminary Q1 2026 revenue of $118 million, up 39% year-over-year
- Testing services revenue of $91 million, up 48% year-over-year
- Testing volume of 54,900, up 17% year-over-year
- Transition services agreement for at least 6 months at Eurobio's expense
- Eurobio grants CareDx exclusive distribution rights for post-transplant monitoring tests in North America
Financial Impact
$170 million cash proceeds from divestiture, $118 million in Q1 revenue
Risk Factors
- Execution risk in transitioning the divested business
- Potential disruption to operations during the 6-month transition period
- Dependence on Eurobio for future supply of divested products
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-043970 |
| Document: tm2611749d1_8k.htm | 0001104659-26-043970 |
| Document: tm2611749d1_ex99-1.htm | 0001104659-26-043970 |
| Document: 0001104659-26-043970-index-headers.html | 0001104659-26-043970 |
| Document: 0001104659-26-043970-index.html | 0001104659-26-043970 |
| Document: 0001104659-26-043970.txt | 0001104659-26-043970 |
| 8-K Data (Synthetic) | 0001104659-26-043970 |
Track record
16 reports on CDNA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $77.88 Now $73.72 −5.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $77.88 Now $73.72 −5.34% settles Feb 11
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $81.17 Now $73.72 −9.18% settles Feb 9
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $80.77 Now $73.72 −8.73% settles Feb 8
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $78.56 Now $73.72 −6.16% settles Feb 4
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $87.41 Now $73.72 −15.66% settles Jan 28
- Oct 29, 202618d ago Institutional Cluster Bearish 4/10 Entry $71.52 Now $73.72 −3.08% settles Jan 27
- Aug 6, 202614w ago Insider Cluster Neutral 3/10 Entry $46.69 to $86.54 Now $73.72 +57.89% ▲ +85.34% +87.47% vs SPY
- Aug 4, 202614w ago 144 Neutral 2/10 Entry $45.50 Now $73.72 +62.02% No price data
- Jul 17, 202617w ago Insider Cluster Neutral 4/10 Entry $39.73 Now $73.72 +85.55% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers